OS Therapies Inc. Files S-1 for Public Offering

TL;DR

OS Therapies Inc. just filed an S-1, looks like they're going public. Get ready for some pharma action.

AI Summary

OS Therapies Inc. filed an S-1 registration statement on January 31, 2025, indicating its intent to offer securities. The company, incorporated in Delaware with its principal executive offices in Grasonville, Maryland, operates in the pharmaceutical preparations sector. Paul A. Romness serves as the President and Chief Executive Officer.

Why It Matters

This S-1 filing signals OS Therapies Inc.'s move towards becoming a publicly traded company, which could lead to increased capital for research and development or expansion, potentially impacting the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As a company filing an S-1, OS Therapies Inc. is in the early stages of a public offering, which inherently carries risks associated with market reception and regulatory processes.

Key Numbers

• 333-284631 — SEC File Number (Identifies the specific SEC registration filing.)
• 25578644 — Film Number (Internal SEC processing number for the filing.)

Key Players & Entities

• OS Therapies Inc. (company) — Registrant
• January 31, 2025 (date) — Filing Date
• Delaware (jurisdiction) — State of Incorporation
• Grasonville, Maryland (location) — Principal Executive Offices
• Paul A. Romness (person) — President and Chief Executive Officer
• 2834 (industry_code) — Standard Industrial Classification (SIC)

FAQ

Key Financial Figures

• $0.001 — Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Stoc
• $1.95 — of our shares on the NYSE American was $1.95 per share. Investing in our shares is
• $6,400,000 — blic offering on July 31, 2024, raising $6,400,000 in gross offering proceeds. The Privat
• $4 — arrant Shares"), at a price per Unit of $4.00, for aggregate gross proceeds of not
• $6 million — gregate gross proceeds of not less than $6 million and not more than $10 million (the "Pri
• $10 million — less than $6 million and not more than $10 million (the "Private Placement"). At two closi
• $7,103,000 — Placement expenses, were approximately $7,103,000. The Purchase Agreement requires us to
• $159,685 — kline received an aggregate cash fee of $159,685 and the right to receive Agent Warrants
• $79,723 — Ceros received an aggregate cash fee of $79,723 and the right to receive Agent Warrants

Filing Documents

• ea0229188-01.htm (S-1) — 6363KB
• ea022918801ex5-1_ostherap.htm (EX-5.1) — 16KB
• ea022918801ex23-1_ostherap.htm (EX-23.1) — 3KB
• ea022918801ex-fee_ostherap.htm (EX-FILING FEES) — 18KB
• tos_logo.jpg (GRAPHIC) — 83KB
• tflowchart_001.jpg (GRAPHIC) — 318KB
• ex5-1_001.jpg (GRAPHIC) — 16KB
• ex5-1_002.jpg (GRAPHIC) — 8KB
• 0001213900-25-008855.txt ( ) — 16871KB
• ostx-20240930.xsd (EX-101.SCH) — 72KB
• ostx-20240930_cal.xml (EX-101.CAL) — 32KB
• ostx-20240930_def.xml (EX-101.DEF) — 333KB
• ostx-20240930_lab.xml (EX-101.LAB) — 514KB
• ostx-20240930_pre.xml (EX-101.PRE) — 350KB
• ea0229188-01_htm.xml (XML) — 2797KB

RISK FACTORS

RISK FACTORS 12 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 48

USE OF PROCEEDS

USE OF PROCEEDS 49 DIVIDEND POLICY 49

MANAGEMENT'S DISCUSSION AND ANALYSIS OFFINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OFFINANCIAL CONDITION AND RESULTS OF OPERATIONS 51

BUSINESS

BUSINESS 62 MANAGEMENT 81

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 89

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 94 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 95

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 97 DESCRIPTION OF PRIVATE PLACEMENT 104 SELLING STOCKHOLDERS 106 PLAN OF DISTRIBUTION 109 LEGAL MATTERS 111 EXPERTS 111 WHERE YOU CAN FIND MORE INFORMATION 111 INDEX TO FINANCIAL STATEMENTS F -1 i Table of Contents ABOUT THIS PROSPECTUS Neither we nor the selling stockholders authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. We are not, and the selling stockholders are not, making an offer of these securities in any jurisdiction where such offer is not permitted. The industry and market data and certain other statistical information used throughout this prospectus are from our own research, surveys or studies conducted by third parties and industry or general publications. Industry publications and third -party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe that these sources are reliable; however, we have not independently verified the information contained in such publications. While we are not aware of any mis

View Full Filing

View this S-1 filing on SEC EDGAR